Vebreltinib for Previously Treated Astrocytoma, IDH-Mutant, Grade 4, and Glioblastoma, IDH Wild-Type with PTPRZ1-MET Fusion Gene: A Multicenter, Phase III Randomized, Open-Label Trial.

Cancer Commun (Lond) · 2026 · PMC12976379 · PMID 41821581

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

The HR of 0.58 (95% CI, 0.33 to 1.03; stratified log-rank P = 0.057) indicated a favorable trend toward improved survival with vebreltinib, although the difference did not reach statistical significance (Fig.

also in 993 other papers

did not reach statistical significanceno p-value reported

The HR of 0.58 (95% CI, 0.33 to 1.03; stratified log-rank P = 0.057) indicated a favorable trend toward improved survival with vebreltinib, although the difference did not reach statistical significance (Fig.

also in 75,281 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Vebreltinib for Previously Treated Astrocytoma, &lt;i&gt;IDH&lt;/i&gt;-Mutant, Grade 4, and Glioblastoma, &lt;i&gt;IDH&lt;/i&gt; Wild-Type with &lt;i&gt;PTPRZ1-MET&lt;/i&gt; Fusion Gene: A Multicenter, Phase III Randomized, Open-Label Trial.

The sentences

Vebreltinib for Previously Treated Astrocytoma, <i>IDH</i>-Mutant, Grade 4, and Glioblastoma, <i>IDH</i> Wild-Type with <i>PTPRZ1-MET</i> Fusion Gene: A Multicenter, Phase III Randomized, Open-Label Trial.